Ocuphire Pharma Investor Presentation Deck

APX3330 History and Ref-1 Inhibition Mechanism Ref-1 Involved in Key Pathways that Contribute to Diabetic Retinopathy and DME Ocuphire Mechanism of Action - Ref-1 Inhibition PHARMA Hypoxia ↓ Ref-1 HIF-1a Anti-VEGF VEGF (Signaling Cascade) LucentisⓇ EYLEAⓇ APX3330 — Neovascularization (H Logsdon et al (2018), Li et al (2014). Inflammation Ref-1 NF-kB TNF-a Chemokines Other Growth Factors (Signaling Cascade) Steroids ● • Ref-1 (reduction-oxidation effector factor-1), a novel target for retinal diseases, is a transcription factor regulator of angiogenesis (VEGF) and inflammation (NFkB) Unique dual MOA decreases abnormal angiogenesis and inflammation • Anti-VEGF injections do not target inflammation • Previously developed by Eisai for hepatic inflammatory indications and by Apexian for solid tumors in 11 Phase 1 and 2 trials ● ● Extensively studied in over 20 in-vitro and animal studies with favorable efficacy and safety 15

View entire presentation